Page last updated: 2024-12-08
cysteinylcysteine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cysteinylcysteine: RN given refers to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cys-Cys : A dipeptide formed from two L-cysteine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 152238 |
CHEBI ID | 131608 |
SCHEMBL ID | 296933 |
MeSH ID | M0134845 |
Synonyms (16)
Synonym |
---|
cysteinylcysteine |
(2r)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoic acid |
18048-87-8 |
CHEBI:131608 |
l-cys-l-cys |
h-cys-cys-oh |
cys-cys |
h-l-cys-l-cys-oh |
l-cysteinyl-l-cysteine |
l-cysteine, n-l-cysteinyl- |
SCHEMBL296933 |
cysteinyl-cysteine |
DTXSID70939338 |
n-(2-amino-1-hydroxy-3-sulfanylpropylidene)cysteine |
Q27225218 |
AKOS040751366 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
Role | Description |
---|---|
Mycoplasma genitalium metabolite | Any bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
---|---|
dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (7.69) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.69) | 29.6817 |
2010's | 10 (76.92) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.08
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.08) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |